Spinal Muscular Atrophy is the leading genetic cause of death for infants. However you are impacted, we have information for you.
News Feed
Scholar Rock Issues Community Statement with Update on SRK-015 in Patients with Types 2 and 3 SMA
Scholar Rock, a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, ...
NeurologyLive Article Now Available, Featuring an Interview with Cure SMA’s Dr. Mary Schroth
Through Cure SMA’s partnership with NeurologyLive, a new patient-centered article, “Early Intervention in SMA: How Access to Therapy Will Alter ...
Cure SMA Publishes Paper in Partnership with NeurologyLive on Impact of COVID-19
Cure SMA has published a paper, titled “Spinal Muscular Atrophy and COVID-19: Guidance and Resources for Providers,” in partnership with ...
Community Spotlight
Community Spotlight: Perspectives from Spencer Cook, Registered Accessibility Specialist
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we have been posting ...
Community Spotlight: Kayley Shade of Sioux Falls Storm
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting ...
Community Spotlight: AJ Brockman of Brewhouse Gallery and Kelsey City Brewing Company
October is National Disability Employment Awareness Month, with an official theme of Increasing Access and Opportunity. Throughout the month, we will be posting ...
Cure SMA is committed to local support.
Find resources or a treatment site in your area.
Since 1984, we’ve invested $82 million in the research that has made today’s breakthroughs possible. We advance a comprehensive research program, attacking SMA from all sides.
The Cure SMA Care Center Network
Local, evidenced-based care centers, designed to develop an evidence-based standard of care to improve the lives of all those affected by SMA.